biological therapy (treatment-naive). Data were collected from the pharmacy outpatient dispensing programme and the clinical history.

**Results** 46 treatment-naive patients started treatment, mean age 43 (17–83), 58.7% men. They were treated with: adalimumab (20 patients), infliximab (17) and ustekinumab (9); none with etanercept.

**Abstract CPC-148 Table 1**

<table>
<thead>
<tr>
<th></th>
<th>Adalimumab</th>
<th>Infliximab</th>
<th>Ustekinumab</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lost to follow-up</td>
<td>5% (1/20)</td>
<td>23.5% (4/17)</td>
<td>22% (2/9)</td>
</tr>
<tr>
<td>Continuing treatment</td>
<td>40% (8/20)</td>
<td>29.4% (5/17)</td>
<td>67% (6/9)</td>
</tr>
<tr>
<td>Withdrawal/Discontinuation by doctor</td>
<td>5% (1/20)</td>
<td>5.9% (1/17)</td>
<td>11% (1/9)</td>
</tr>
<tr>
<td>Discontinuation due to good response</td>
<td>20% (4/20)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Change of treatment</td>
<td>30% (6/20)</td>
<td>41.2% (7/17)</td>
<td>–</td>
</tr>
</tbody>
</table>

The causes of the discontinuation/change of treatment were:

**Abstract CPC-148 Table 2**

<table>
<thead>
<tr>
<th></th>
<th>Adalimumab</th>
<th>Infliximab</th>
<th>Ustekinumab</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lack of efficacy</td>
<td>27.2% (3/11)</td>
<td>25% (2/8)</td>
<td>–</td>
</tr>
<tr>
<td>Adverse reactions</td>
<td>18.2% (2/11)</td>
<td>37.5% (3/8)</td>
<td>–</td>
</tr>
<tr>
<td>Lack of response + adverse reactions</td>
<td>18.2% (2/11)</td>
<td>12.5% (1/8)</td>
<td>–</td>
</tr>
<tr>
<td>Lack of adherence</td>
<td>–</td>
<td>25% (2/8)</td>
<td>–</td>
</tr>
<tr>
<td>Good response</td>
<td>36.4% (4/11)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Other reasons</td>
<td>–</td>
<td>–</td>
<td>100% (1/1)</td>
</tr>
</tbody>
</table>

Adverse reactions that caused withdrawal or change were:

**Abstract CPC-148 Table 3**

<table>
<thead>
<tr>
<th></th>
<th>Adalimumab</th>
<th>Infliximab</th>
<th>Ustekinumab</th>
</tr>
</thead>
<tbody>
<tr>
<td>Autoimmune hepatitis</td>
<td>25% (1/4)</td>
<td>25% (1/4)</td>
<td>25% (1/4)</td>
</tr>
<tr>
<td>Asthma and mood changes</td>
<td>25% (1/4)</td>
<td>25% (1/4)</td>
<td>25% (1/4)</td>
</tr>
<tr>
<td>Psoriatic arthritis</td>
<td>25% (1/4)</td>
<td>25% (1/4)</td>
<td>25% (1/4)</td>
</tr>
<tr>
<td>Pharyngitis and candidiasis</td>
<td>25% (1/4)</td>
<td>25% (1/4)</td>
<td>25% (1/4)</td>
</tr>
<tr>
<td>Acute infusion reactions</td>
<td>75% (3/4)</td>
<td>75% (3/4)</td>
<td>75% (3/4)</td>
</tr>
<tr>
<td>Psoriatic arthropathy</td>
<td>25% (1/4)</td>
<td>25% (1/4)</td>
<td>25% (1/4)</td>
</tr>
</tbody>
</table>

**Conclusions** The first biological in treatment-naive patients was adalimumab, and infliximab and ustekinumab. Ustekinumab was the biological drug that achieved the best retention rate. Several patients discontinued their treatment with adalimumab because of good response, since it can be used in intermittent treatment schemes. Change in treatment was more frequent with infliximab, mainly because of infusion reactions. Ustekinumab was the only biological that didn’t cause adverse reactions that caused withdrawal or change.

No conflict of interest.

**CPC-149 TRIMEBUTINE: A CASE OF ABUSE AND POSSIBLE DEPENDENCE**

A Guillermet, M Geneste, C Combe, H Hida. Hospital, Pharmacy, Valence Cedex, France

**Background** Trimebutine has an agonist effect on digestive tract and brain mu, kappa, and delta opiate receptors.

**Purpose** To describe a case report of an abuse and a possible dependence on trimebutine.

**Materials and Methods** Medical record review and literature search about trimebutine dependence.

**Results** A 46-year-old woman with a history of Chronic Intestinal Pseudo-Obstruction (CIPO) was prescribed amikacin and trimebutine in the hospital since 2011. Her gastroenterologist initially prescribed trimebutine at 100 mg intravenously three times a day, with a possibility of 100 mg shots if necessary without a maximum dose. At the same time she obtained another prescription by her general practitioner (50 mg IV if needed). Finally 753 ampoules were delivered in seven weeks (15 a day). This overconsumption alarmed the pharmaceutical team and a literature review was made. Dependence is described in a French register: six cases of intravenous abuse or dependence were reported between 1993 and 2009. At high doses trimebutine is cardiotoxic (bradycardia, rhythm disorders) and neurotoxic (convulsions). We alerted the prescribers and reported this abuse to our pharmacovigilance centre. A questionnaire to evaluate the level of dependence was sent to the general practitioner.

Once the general practitioner had been informed, the gastroenterologist alone managed her CIPO treatment and a new prescription was established with a trimebutine posology more consistent with the marketing authorization.

**Conclusions** Provision from a hospital enabled us to detect the overuse of this drug. Dependence is difficult to prove and drug abuse screening test in the assessment of DSM IV should be used to establish it.

No conflict of interest.

**CPC-150 TUBERCULOSIS AND SYSTEMIC DISEASES**

M Razgaallah Khrouf, M Turki, N Kraiem, M Guerfali. Hospital the “Rabta”, Pharmacy, Tunis, Tunisia

**Background** The immunosuppression of systemic diseases makes the management of patients with tuberculosis more complicated.

**Purpose** To monitor the clinical evolution of tuberculosis in patients suffering from systemic diseases.

**Materials and Methods** A retrospective study, from 1998 to 2012, in the internal medicine service in Rabta hospital, Tunisia, of 9 patients (8 women and a man, median age: 54 years) suffering from connective tissues disease, treated by corticosteroids linked in one or several treatments to immunosuppressants, who subsequently developed tuberculosis.

**Results** The median time to diagnosis was 116 days (7d – 1 year). The location of the tuberculosis was pulmonary (n = 2), ganglionic (n = 3), urogenital (n = 2), and tubercular spondylodiscitis (n = 1), more than one location (n = 1). The diagnosis of tuberculosis was confirmed by bacteriology (n = 4) four cases, histologically (n = 5) and by a test treatment (n = 1). Systemic illnesses were: systemic lupus erythematosus (n = 5), Gougerot-Sjögren syndrome (secondary or primary) (n = 3), sarcoidosis (n = 1), systemic sclerosis linked to pernicious anaemia (n = 1), rheumatoid arthritis (patient 2 linked to lupus) (n = 1) and multiple autoimmune syndrome (n = 1). The diagnosis of systemic illness was made before that of tuberculosis in 8 patients and concomitantly in only one. Under treatment by four drugs then by two drugs, the evolution of tuberculosis was favourable in five of nine patients. One of the patients developed an allergy in isoniazid and resistance to the anti-tubercular treatment. Five of our patients recovered from their illness.

**Conclusions** This study confirms the often extra-pulmonary character of tuberculosis in patients with systemic disease as well as the difficulty of diagnosis and problems multiplied by this association.

No conflict of interest.

**CPC-151 TYPE OF CANCER AND RISK FACTORS IN HIV PATIENTS ON ANTIRETROVIRAL TREATMENT**

L Gaseras, MC Meriel, L Corrales, P San Miguel, MJ Vazquez, *M Segura, B Rubio, C Calderon, RM Catalá. Hospital Universitario de Móstoles, Pharmacy, Móstoles (Madrid), Spain
Background  HIV infection is associated with increased risk of cancer:

Purpose: To analyse patients with antiretroviral therapy and chemotherapy, type of cancer and associated risk factors.

Materials and Methods: Descriptive study of patients with antiretroviral and chemotherapy between 2004–2011, extracting data from medical records and the Farmatools programme, analysing using SPSS 11.0.

Results: 33 patients were obtained (37.7% of all HIV patients on antiretroviral treatment); 82% men: 16 with ADC (11 NHL, 3 KS, and 2 with NHL and KS) and 17 with NADC (5 HL, 3 lung cancer, 3 head-neck, 3 anal, 1 ovary, 1 gastric and 1 chronic lymphocytic leukaemia). When cancer was diagnosed patients presented: CD4<200 cells/μl (27.3%), detectable viral load (VL) (33.3%), C3 category (63.6%), smokers (63.6%), human papillomavirus (HPV) (61.1%), Epstein Barr virus (21.2%), human herpes virus 8 (HHV8) (21.2%), hepatitis B-C (48.5%), intravenous drug addict (24.2%). 6 patients died.

80% KS patients and 66.7% head-neck cancer had CD4<200 (P < 0.036). 62.5% of those who died presented CD4<200 (P = 0.009). 66.6% of anal cancer patients presented HIV (P = 0.006). 100% of KS presented HHV8 (P = 0.002).

Conclusions: 3.7% of HIV patients on treatment developed neoplasms, more than 50% were NADC, of which 88% started in status when cancer was diagnosed.

No conflict of interest.

International posters

Background: HIV infection is associated with increased risk of cancer:

Purpose: To analyse patients with antiretroviral therapy and chemotherapy, type of cancer and associated risk factors.

Materials and Methods: Descriptive study of patients with antiretroviral and chemotherapy between 2004–2011, extracting data from medical records and the Farmatools programme, analysing using SPSS 11.0.

Results: 33 patients were obtained (37.7% of all HIV patients on antiretroviral treatment); 82% men: 16 with ADC (11 NHL, 3 KS, and 2 with NHL and KS) and 17 with NADC (5 HL, 3 lung cancer, 3 head-neck, 3 anal, 1 ovary, 1 gastric and 1 chronic lymphocytic leukaemia). When cancer was diagnosed patients presented: CD4<200 cells/μl (27.3%), detectable viral load (VL) (33.3%), C3 category (63.6%), smokers (63.6%), human papillomavirus (HPV) (61.1%), Epstein Barr virus (21.2%), human herpes virus 8 (HHV8) (21.2%), hepatitis B-C (48.5%), intravenous drug addict (24.2%). 6 patients died.

80% KS patients and 66.7% head-neck cancer had CD4<200 (P < 0.036). 62.5% of those who died presented CD4<200 (P = 0.009). 66.6% of anal cancer patients presented HIV (P = 0.006). 100% of KS presented HHV8 (P = 0.002).

Conclusions: 3.7% of HIV patients on treatment developed neoplasms, more than 50% were NADC, of which 88% started in status when cancer was diagnosed.

No conflict of interest.

CPC-152 USE OF OMAZILUMAB IN CHRONIC COLD URTICARIA: A CASE REPORT

doi:10.1136/ejpharm-2013-000276.609

O Abdo, C Sansac, MP Ponrouch, I Roch-Torreilles, JL Allaz, P Rambourg. CHRU de Montpellier, hérault, Montpellier, France

Background: Omalizumab is a recombinant humanised monoclonal antibody which prevents the binding of IgE to the high-affinity receptor type I (FcεRI). A complicated series of reactions results in a reduction of free IgE responsible for the allergic inflammatory cascade. Omalizumab is indicated as add-on therapy to improve asthma control in adults and adolescents (from 12 years). In addition, several studies show that omalizumab is effective in the treatment of chronic urticaria.

Purpose: We report the case of a patient with chronic cold urticaria resistant to conventional treatments.

Materials and Methods: The patient was a 67-year-old man, who had suffered from chronic urticaria for over 30 years. The disease was disclosed by pressure urticaria, which had been neglected for a long time. It then turned into a cold urticaria in the 90s. The latter showed itself in 2002 as the patient experienced an anaphylactic shock in a bath at 24°C.

Results: Several lines of treatment, all unsuccessful, were tested on the patient: high-dose H1 antihistamine, montelukast, methotrexate, anakinra. In view of this therapeutic impasse, omalizumab appeared as an alternative: doses of 375 mg were administered to him every 15 days as a start. In total, 12 treatments were performed in dermatology outpatients. No side effects were encountered except for an episode of nausea. The results were: a decrease in consumption of H1 antihistamine, ice test negative and significant clinical improvement of his urticaria.

Conclusions: In view of the results obtained for this patient, omalizumab appears to be an alternative for treating chronic urticaria in treatment failure. Indeed, it is well tolerated, the risk-benefit ratio is positive, the only problem is the cost incurred for such care.

No conflict of interest.

CPC-153 WARD PHARMACIST: MANAGING INTERACTIONS IN THE DEPARTMENT OF HEMATOLOGY AND BONE MARROW TRANSPLANTATION

doi:10.1136/ejpharm-2013-000276.610

G Saibene, F Braia, E Toﬁgli, G Antonacci, F Festinesi, M Mazzer, V Di Mauro. Fondazione IRCCS Istituto Nazionale Dei Tumori, Farmacia, Milano, Italy

Background: The Milan National Cancer Institute Pharmacy began a collaboration with the haematology and bone marrow transplantation (ETMO) department, to optimise concomitant conditioning protocols of bone marrow transplants; the pharmacokinetics and pharmacodynamics are affected by the high doses of chemotherapy administered. The drugs analysed were those in the conditioning schedules used in accordance with international guidelines.

Purpose: To provide a practical guide for managing drug interactions between the drugs commonly used by ETMO and those in the transplant conditioning schedules.

Materials and Methods: The presence of the ward pharmacist, funded by the Italian Haematology Society, allowed the daily management of treatment to be investigated. Databases were used (Micromedex, Codifa) and literature meta-analyses were conducted, in order to obtain the pharmacokinetic and pharmacodynamic characteristics of these drugs and possible interactions.

Results: Within our Institute, 72 transplants that used conditioning were performed in a year, 32 autologous and 40 allogeneic. In particular, 28 transplants used a high-dose melphalan scheme, 28 used thiotepa/fludarabine/cyclophosphamide, 4 used BEAM, 4 used TBI/fludarabine/cyclophosphamide and 8 used the KROGER scheme. Therefore the interactions between drugs used in the protocols themselves and the drugs commonly used within the department by transplant patients were analysed. For this purpose the following drugs were considered: cyclosporin, allopurinol, acetazolamide and IFP. Following this analysis, it was shown that there were significant interactions between the drugs used in the conditioning scheme and drugs commonly used in patients with bone marrow transplants.

Conclusions: The pharmacist set up a means of enabling a clinician to browse for a more informed choice: dedicated schemes are being developed, in which they report any interactions observed, associated with the treatment protocols. All this has therefore contributed to the rational use of the drugs and resources, for example the use of antifungals after transplantation and not before, and the introduction of pantoprazole instead of omeprazole. A future goal will be the analysis of the interactions between the drugs and concomitant haematology chemotherapy.

No conflict of interest.

International posters

INT-009 POINT PREVALENCE STUDIES ON ANTIBIOTIC USAGE AT THE CHILDRENS’S UNIVERSITY HOSPITAL

doi:10.1136/ejpharm-2013-000276.611

I Svetinš, D Mozgiç. Children’s University Hospital in Riga, Latvia.

Background: Due to higher use of broad spectrum agents in the treatment of both adults and children, hospitals are considered to be centres of antimicrobial resistance. According to several studies, approximately 60% of hospitalised children will receive at least one antibiotic.